Skip to content

Congress Materials

Acadia shares innovative research, medical information, and trial data at select medical conferences and congresses. These resources are reflective of what was presented at the scientific meeting; no changes are made post-meeting.

This page is intended as an educational resource for U.S. healthcare professionals. The list of congress materials below may contain information about doses, uses, formulations, and populations different from product labeling or contain information about investigational compounds or uses not approved by the FDA. Please refer to the product’s Full Prescribing Information.

Search
Congress
Molecule
Area of Focus
Filters applied:
Apply Filters to Show Results
  • December 6, 2024
  • Congress Poster
Real-World Trofinetide Dosing for Rett Syndrome: The LOTUS Study

CNS 2024

  • December 4, 2024
  • Congress Poster
An Open-Label Study to Investigate the 5-HT2A Receptor Occupancy of ACP-204 With the PET Ligand [18F]Altanserin in Healthy Adult Males

ACNP 2024

  • December 4, 2024
  • Congress Poster
Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies

ACNP 2024

  • December 4, 2024
  • Congress Poster
Nonclinical Characterization of ACP-204, a Novel Second-Generation 5-HT2A Inverse Agonist

ACNP 2024

  • December 4, 2024
  • Congress Poster
Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies

NEI 2024

  • December 4, 2024
  • Congress Poster
Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: An Open-Label Extension Study

NEI 2024

  • December 4, 2024
  • Congress Poster
Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies

NEI 2024

  • December 4, 2024
  • Congress Poster
Mortality in Patients With Parkinson’s Disease Psychosis Using Pimavanserin Versus Other Antipsychotics

NEI 2024

  • December 4, 2024
  • Congress Poster
Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: an Open-Label Extension Study

NEI 2024

  • December 4, 2024
  • Congress Poster
Patients with Parkinson’s Disease Psychosis and Dementia: Analysis of Healthcare Resource Utilization and Time to Long Term Care Admission among US Medicare Beneficiaries Initiating Pimavanserin versus Other-Atypical Antipsychotics

PSG 2024

  • December 4, 2024
  • Congress Poster
Safety and Efficacy of Pimavanserin in Patients With Parkinson’s Disease Dementia or Dementia With Lewy Bodies Experiencing Dementia-Related Psychosis in the HARMONY Study

PSG 2024

  • December 4, 2024
  • Congress Poster
Duration of Illness and Complete Response to Pimavanserin in Parkinson’s Disease Psychosis: Analysis of Pooled Clinical Trial Data

PSG 2024

  • December 4, 2024
  • Congress Poster
Mortality in Patients With Parkinson’s Disease Psychosis Using Pimavanserin Versus Other Antipsychotics

PSG 2024

  • December 4, 2024
  • Congress Poster
Safety and Efficacy of Pimavanserin in Patients With Parkinson’s Disease Dementia or Dementia With Lewy Bodies Experiencing Dementia-Related Psychosis in HARMONY

PSYCH 2024

  • December 4, 2024
  • Congress Poster
Duration of illness and complete response to pimavanserin in Parkinson’s disease psychosis: analysis of pooled clinical trial data

PSYCH 2024

  • December 4, 2024
  • Congress Poster
Mortality in Patients With Parkinson’s Disease Psychosis Using Pimavanserin Versus Other Antipsychotics

PSYCH 2024

  • December 4, 2024
  • Congress Poster
Healthcare Resource Utilization and Time to Long Term Care Admission among Patients with Parkinson’s Disease Psychosis with Co-Existing Dementia initiated on Pimavanserin vs Quetiapine: Analysis of US Medicare Beneficiaries

PSYCH 2024

  • October 2, 2024
  • Congress Poster
Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Open-label Studies

World Rett

  • October 2, 2024
  • Congress Poster
Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study

World Rett

  • October 2, 2024
  • Congress Poster
Rett syndrome behaviour questionnaire (RSBQ): Are longitudinal RSBQ total scores associated with genotype and mobility, weight and seizure frequency trajectories?

World Rett

  • October 2, 2024
  • Congress Poster
Rett syndrome behaviour questionnaire (RSBQ): The natural history of RSBQ scores

World Rett

  • October 2, 2024
  • Congress Poster
Trofinetide for the treatment of girls aged two to four years with Rett syndrome: Final results from the open-label DAFFODIL study

World Rett

  • October 2, 2024
  • Congress Poster
Trofinetide for the treament of Rett syndrome: Long-term safety and efficacy results from the open-label LILAC and LILAC-2 studies

World Rett

  • October 2, 2024
  • Congress Poster
Risk factors of aspiration, associated respiratory complications, and healthcare utilization among individuals with Rett syndrome; A US RETT Center of Excellence database study

World Rett

  • October 2, 2024
  • Congress Poster
Common diagnostic reasons for hospitalizations and emergency department visits among females with Rett syndrome in the United States

World Rett

  • October 2, 2024
  • Congress Poster
The impact of epilepsy on health care resource utilization in patients with Rett syndrome

World Rett

  • June 29, 2024
  • Congress Poster
Clinical, humanistic, and economic burden of Rett syndrome: A systematic review

EAN

  • June 22, 2024
  • Congress Poster
Use of modified Functional Scale Questionnaire to assess functional outcomes in patients with Parkinson’s disease psychosis and treated with pimavanserin

ATMRD

  • June 20, 2024
  • Oral Presentation
Use of modified Functional Scale Questionnaire to assess functional outcomes in patients with Parkinson’s disease psychosis and treated with pimavanserin

Psych Update

  • June 20, 2024
  • Congress Poster
Use of modified Functional Scale Questionnaire to assess functional outcomes in patients with Parkinson’s disease psychosis and treated with pimavanserin

Psych Update

  • June 18, 2024
  • Congress Poster
Assessing Experiences With Trofinetide for Rett Syndrome; Interviews With Caregivers of Patients in LAVENDER, LILAC, and LILAC-2 Studies

IRSF

  • June 18, 2024
  • Congress Poster
Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: the LOTUS study

IRSF

  • June 18, 2024
  • Congress Poster
Trofinetide for the Treatment of Rett Syndrome: Long-Term Safety and Efficacy Results from the Open-Label LILAC-2 Study

IRSF

  • April 15, 2024
  • Congress Poster
Use of modified Functional Scale Questionnaire to assess functioning in patients with Parkinson’s disease psychosis treated with pimavanserin

AAN

  • April 13, 2024
  • Oral Presentation
Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Open-label Studies

AAN

  • April 13, 2024
  • Oral Presentation
Trofinetide for the Treatment of Girls Aged Two to Four Years With Rett Syndrome: Final Results From the Open-Label DAFFODIL Study

AAN

  • April 6, 2024
  • Oral Presentation
A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pimavanserin as adjunctive treatment for the negative symptoms of schizophrenia (ADVANCE-2)

SIRS

  • February 17, 2024
  • Congress Poster
The role of therapeutic professionals and tools for assessing therapeutic progress in Rett syndrome

APTA

  • December 5, 2023
  • Congress Poster
Use of modified Functional Scale Questionnaire to assess functional outcomes in patients with Parkinson’s disease psychosis and treated with pimavanserin

ACNP

  • December 1, 2023
  • Congress Poster
Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Patients in LAVENDER, LILAC, and LILAC-2 Studies

AES

  • December 1, 2023
  • Congress Poster
Trofinetide Treatment of Rett Syndrome is not Associated with Seizure Incidence or Interactions with Antiepileptic Drugs

AES

  • December 1, 2023
  • Congress Poster
Trofinetide for the Treatment of Rett Syndrome: Long-Term Safety and Efficacy Results from the Open-Label LILAC-2 Study

AES

  • September 11, 2023
  • Congress Poster
Limited potential for interactions between trofinetide, a new treatment for Rett Syndrome, and drugs metabolized by CYP3A4

ACCP

  • September 11, 2023
  • Congress Poster
In silico physiologically based pharmacokinetic model of the effect of hepatic impairment on trofinetide exposures

ACCP

  • August 28, 2023
  • Congress Poster
A 16-week open-label study of the effects of treatment with pimavanserin on activities of daily living in subjects with Parkinson's disease psychosis (PDP)

MDS

  • August 28, 2023
  • Congress Poster
Incremental hospitalizations and associated costs of co-existing dementia in patients with Parkinson’s disease psychosis: an analysis of US Medicare beneficiaries

MDS

  • July 18, 2023
  • Congress Poster
Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms: a Phase 3b study

AAIC

  • June 5, 2023
  • Congress Poster
Factors associated with behaviors measured by the Rett Syndrome Behaviour Questionnaire in Rett syndrome

IRSF

  • June 5, 2023
  • Congress Poster
Characterizing patients with Rett syndrome in the United States: a real-world analysis of the Rett Syndrome Natural History Study database

IRSF

  • June 5, 2023
  • Congress Poster
Trofinetide for the treatment of Rett syndrome: results from the open-label LILAC study

IRSF

  • May 30, 2023
  • Congress Poster
Incremental burden of dementia among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries

ASCP (ClinPsych)

  • May 10, 2023
  • Congress Poster
The key role of therapeutic professionals in Rett syndrome care pathway

ISPOR

  • May 8, 2023
  • Congress Poster
Characteristics, comorbid GI conditions, and treatment patterns among individuals diagnosed with Rett syndrome

ISPOR

  • May 8, 2023
  • Congress Poster
Tools for assessing therapeutic progress in patients with Rett syndrome

ISPOR

  • April 27, 2023
  • Congress Poster
Treatment with trofinetide shows benefit compared with placebo in the ability to communicate in individuals with Rett syndrome

AAN

  • April 27, 2023
  • Congress Poster
Trofinetide for the treatment of Rett syndrome: an open-label study in girls aged 2–4 years

AAN

  • March 23, 2023
  • Congress Poster
Elevated healthcare resources utilization and costs among individuals diagnosed with Rett syndrome

AMCP

  • March 23, 2023
  • Congress Poster
Clinical management of Rett syndrome in the real world: a physician survey

AMCP

This is now a publication.

  • March 23, 2023
  • Congress Poster
Patients treated with pimavanserin or quetiapine for Parkinson’s disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries

AMCP

  • March 22, 2023
  • Congress Poster
Population pharmacokinetic modelling to confirm weight-based banded dosing and exposure-response efficacy and safety analyses to support trofinetide treatment in Rett syndrome

ASCPT

This is now a publication.

  • March 22, 2023
  • Congress Poster
Population pharmacokinetic modelling to predict trofinetide exposure and exposure-response safety analyses in girls with Rett syndrome aged 2-4 years

ASCPT

  • December 7, 2022
  • Congress Poster
Pimavanserin treatment of hallucinations and delusions in patients with Parkinson’s disease dementia: post hoc analysis of the HARMONY trial

ACNP

  • December 6, 2022
  • Congress Poster
Motor-related and cognition-related safety of pimavanserin in patients with Parkinson’s disease psychosis

ACNP

  • December 6, 2022
  • Congress Poster
Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia

ACNP

  • November 16, 2022
  • Congress Poster
A 5-HT2A receptor inverse agonist attenuates morphine withdrawal syndrome in the rat

SfN Malin

  • November 4, 2022
  • Congress Poster
TAME: an observational study to assess the frequency of psychosis-related events in long-term care facilities and the time associated with the management of these events by facility caregiver

ASCP (ConsPharm)

  • November 4, 2022
  • Congress Poster
A 16-week open-label study of the effects of treatment with pimavanserin on activities of daily living in subjects with Parkinson's disease psychosis

NEI

  • October 17, 2022
  • Congress Poster
Mapping the top concerns of caregivers of individuals with Rett syndrome with items on the Rett Syndrome Behaviour Questionnaire to identify clinically meaningful outcomes

NORD

  • October 17, 2022
  • Congress Poster
Trofinetide for the treatment of girls and women aged 2-20 years with Rett syndrome: results from phase 3 trials

NORD

  • October 13, 2022
  • Congress Poster
A phase 1, ascending dose study to assess the potential effects of trofinetide on QTc interval, safety and tolerability, and pharmacokinetics in healthy adults

CNS

  • October 13, 2022
  • Congress Poster
An open-label study of trofinetide for the treatment of Rett syndrome in girls 2 to 4 years of age (DAFFODIL)

CNS

  • October 12, 2022
  • Congress Poster
Gastrointestinal manifestations in pediatric and adult patients with Rett syndrome – an analysis of US claims data

AMCP

This is now a publication.

  • October 12, 2022
  • Congress Poster
Real-world clinical management of individuals with Rett syndrome: a physician survey

Nexus

This is now a publication.

  • September 25, 2022
  • Congress Poster
Population pharmacokinetic modeling and stochastic simulations to support pediatric dose selection of pimavanserin

ACCP

  • September 18, 2022
  • Congress Poster
Pimavanserin treatment of hallucinations and delusions in patients with Parkinson’s disease dementia: post hoc analysis of the HARMONY trial

Psych Congress

  • September 17, 2022
  • Congress Poster
A 16-week open-label study of the effects of treatment with pimavanserin on activities of daily living in subjects with Parkinson's disease psychosis (PDP)

Psych Congress

  • September 17, 2022
  • Congress Poster
Real-world persistency outcomes associated with pimavanserin vs other-AAPs for Parkinson’s disease psychosis: analysis of Medicare beneficiaries from 100% sample

Psych Congress

  • September 16, 2022
  • Congress Poster
Motor-related and cognition-related safety of pimavanserin in patients with Parkinson’s disease psychosis

MDS

  • September 16, 2022
  • Congress Poster
Risk of mortality and antipsychotics in Parkinson’s disease-related psychosis: pimavanserin vs off-label atypical antipsychotics

MDS

  • September 16, 2022
  • Congress Poster
ER visits and hospitalizations among patients treated with pimavanserin or other-AAPs for Parkinson’s disease psychosis: analysis of Medicare beneficiaries

MDS

  • September 15, 2022
  • Oral Presentation
Risk of long-term care admissions among Medicare patients treated with pimavanserin vs. atypical antipsychotics for Parkinson’s disease psychosis

MDS

  • July 31, 2022
  • Congress Poster
Efficacy and safety of pimavanserin in patients with psychosis related to Alzheimer’s dementia in the HARMONY phase 3, randomized discontinuation study: post hoc subgroup analysis

AAIC

  • June 17, 2022
  • Congress Poster
Motor-related and cognition-related safety of pimavanserin in patients with Parkinson’s disease psychosis

ATMRD

  • June 17, 2022
  • Congress Poster
Pimavanserin is not associated with elevated risk of mortality in patients with Parkinson’s disease psychosis

ATMRD

  • June 2, 2022
  • Congress Poster
Risk of mortality associated with pimavanserin compared with other atypical antipsychotics in patients with Parkinson’s disease-related psychosis

ASCP

  • May 26, 2022
  • Congress Poster
Impact of isolation during the COVID-19 pandemic on non-motor symptoms of Parkinson’s disease: a PMD Alliance survey

MDS-PAS

  • May 18, 2022
  • Congress Poster
Healthcare resource utilization patterns in United States patients with Rett syndrome

ISPOR

  • May 13, 2022
  • Congress Poster
Motor-related and cognition-related safety of pimavanserin in patients with Parkinson’s disease psychosis

AGS

  • May 12, 2022
  • Congress Poster
Efficacy, safety, and acceptability of atypical antipsychotics in treating Parkinson’s disease psychosis.: a systematic literature review

AGS

  • May 1, 2022
  • Congress Poster
Retrospective analyses evaluating the risk of mortality associated with pimavanserin or other atypical antipsychotics in patients with Parkinson’s disease psychosis

IAPRD

  • April 26, 2022
  • Congress Poster
Characterizing the journey of Rett syndrome in the United States using the Rett Natural History Study Database

IRSF-ASCEND

  • April 26, 2022
  • Congress Poster
Design and outcome measures of an open label study of trofinetide for the treatment of girls 2 to 5 years of age with Rett syndrome

IRSF-ASCEND

  • April 24, 2022
  • Congress Poster
Pimavanserin treatment of hallucinations and delusions in patients with Parkinson’s disease dementia: post hoc analysis of the HARMONY trial

AAN

  • April 5, 2022
  • Congress Poster
Patient journey and clinical burden of Rett syndrome in the United States

AAN

This is now a publication.

  • April 5, 2022
  • Oral Presentation
Efficacy and safety of trofinetide for the treatment of Rett syndrome: results from the pivotal phase 3 LAVENDER study

AAN

This is now a publication.

  • March 30, 2022
  • Congress Poster
Characteristics, comorbidities, and treatment patterns among male individuals diagnosed with Rett syndrome

AMCP

This is now a publication.

  • March 18, 2022
  • Congress Poster
Natural history of dementia-related psychosis and antipsychotic treatment patterns in older adults in the United States

ADPD

  • March 10, 2022
  • Congress Poster
Antipsychotic medication review documentation and pimavanserin treatment-continuity on outcomes: analysis of Minimum Data Set 3.0 linked with Part D claims

AMDA

98 Results

To report an Adverse Event or Product Complaint please call (844) 422-2342.

Important Note

This page is intended as an educational resource for U.S. healthcare professionals. The list of Acadia-sponsored publications below may contain information about doses, uses, formulations and populations different from product labelling or contain information about investigational compounds or uses not approved by the FDA.

I certify that I am a licensed health care provider in the U.S.

Important Note

You are now being redirected

You are now leaving acadia.com

You are about to leave acadia.com. You will be redirected to a third party website not affiliated with Acadia Pharmaceuticals Inc.
Do you want to continue?

You are leaving our {{LEAVING_REGION}} website and going to our {{ENTERING_REGION}} website, which is in {{ENTERING_LANGUAGE}}.
The information you are about to be referred to may not comply with the local regulatory requirements.
Do you want to continue?

You are now being directed to another Acadia website that contains information about specific treatment(s).
Do you want to continue?

Continue